Mechanism and Efficacy of Mobilization of Granulocyte Colony-Stimulating Factor in the Treatment of Chronic Hepatic Failure

Xing, Tongjing; Xu, Hongtao; Xian, Jianchun; Shen, Meilong; Li, Hao; Ye, Jun; Zhang, Lixin

doi:10.5754/hge12590

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…G-CSF can promote CD34 + hematopoietic stem cell mobilization through regulation of stem cells mobilization-related factors in patients with liver cirrhosis (34) and HBV-associated acute-on-chronic hepatic failure (35). In addition, a recent study revealed that G-CSF was significantly lower in patients with pulmonary embolism in comparison to controls (36).…”

Section: Discussionmentioning

confidence: 99%

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

et al. 2014

View full text Add to dashboard Cite

Background:Immune cells and molecules play a vital role in initiating, maintaining, regulating immunological homeostasis and inflammation in many pathological and physiological processes; however, the changes on expressions and functions of these cells and molecules in hepatitis B virus (HBV) infection have not been elucidated well.Objectives:The current study aimed to determine the expression pattern of different cytokines, chemokines, immune cells in HBV infection and their association with disease progression.Patients and Methods:Sixty-nine patients with chronic HBV infection were enrolled. Five immune cell subsets and 46 cytokines and chemokines were analyzed by flow cytometry and Luminex 200.Results:In comparison to healthy individuals and asymptomatic HBV carriers, expression of CXCL9, CXCL10, CXCL11, and IL-10 were elevated in patients with chronic active HBV and had positive correlation with ALT levels. In contrast, G-CSF, MCP-3, and IFN-γ levels were significantly decreased in patients with chronic active HBV infection in contrast to carriers and healthy individuals; however, these down regulations did not show any correlation with either virological findings or liver inflammation. Although the proportion of CD4+ CD25 high regulatory T cells (Tregs) was higher in patients with HBV infection than in healthy controls, no correlations were found between Tregs and other cytokines or chemokines.Conclusions:CXCR3-associated chemokines might contribute to liver inflammation in chronic hepatitis B, while MCP-3 and G-CSF were inhibited by HBV infection. Host immune response was suppressed as manifested by an increase in CD4+ CD25high Tregs and IL-10 as well as a decrease in IFN-γ. Exploiting the expression pattern of cytokine and chemokine may help to develop a better understanding of chronic HBV infection pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

et al. 2014

View full text Add to dashboard Cite

show abstract

“… 8 – 11 In total, 42 of 94 G-CSF users died from multi-organ failure, whereas 74 of 98 G-CSF non-users died. The pooled analysis of the survival benefit represented an RR of 2.25 (95% CI 1.517 to 3.338, p = 0.000), with no substantial heterogeneity across studies (I 2 = 30.1%, p = 0.232).After excluding the study that applied case-control analysis of a cohort study, 10 the RR increased even further for patients with G-CSF therapy (RR = 2.682, 95% CI 1.732 to 4.151, p = 0.000), indicating no heterogeneity among studies (I 2 = 0.0%, p = 0.666) ( Fig.6 ).…”

Section: Resultsmentioning

confidence: 96%

“…Data on liver function parameters were available in three trials comparing G-CSF with control therapy. 10 , 11 No significant difference was found in prothrombin time (PT) between G-CSF and control therapy groups (OR = −0.064, 95% CI −0.481 to 0.353, p = 0.764). No substantial heterogeneity was detected (I 2 = 61.4%, p = 0.107) ( Fig.…”

Section: Resultsmentioning

confidence: 99%

“…Five clinical trials involving the potential effects of G-CSF in LF patients met the inclusion criteria, and the characteristics of these studies are shown in Table 1 . Among these trials, two were conducted in India, 9 , 11 two were conducted in China, 8 , 10 and one was conducted in the UK. 12 Three of the studies were randomized controlled trials (RCTs), 8 , 9 , 11 and two were prospective cohort studies.…”

Section: Resultsmentioning

confidence: 99%

“… 12 Three of the studies were randomized controlled trials (RCTs), 8 , 9 , 11 and two were prospective cohort studies. 10 , 12 One study only enrolled patients with severe alcoholic hepatitis, 11 one study admitted patients with LF due to acetaminophen overdose, 12 two studies included only patients with hepatitis B virus (HBV)-associated LF, 8 , 10 and the remaining study included LF patients with various etiologies. 9 …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Effects of Granulocyte Colony-Stimulating Factor on Patients with Liver Failure: a Meta-Analysis

Yang

Shi

et al. 2016

JCTH

View full text Add to dashboard Cite

Background and Aims: It remains controversial whether granulocyte colony-stimulating factor (G-CSF) prolongs survival in liver failure (LF) patients. This meta-analysis was performed to evaluate the effect of G-CSF on patients with LF.Methods: PubMed, EMBASE, and Web of Science databases were searched to identify English language randomized controlled trials comparing G-CSF with control therapy published before14 February 2015. A meta-analysis was performed to examine changes in liver function and patient survival. The association was tested using odds ratio (OR) or risk ratio (RR) with 95% confidence intervals (CI).Results: Five randomized controlled trials were eligible for the meta-analysis. Significant amelioration of prothrombin time and total bilirubin in LF patients was attributed to G-CSF therapy (OR, −0.064; 95% CI,−0.481 to 0.353; p< 0.001; and OR, −0.803; 95% CI, −1.177 to −0.430; p = 0.000, respectively). Treatment with G-CSF resulted in improved Model for End-Stage Liver Disease and Child-Turcotte-Pugh scores (OR, −1.741; 95% CI, −2.234 to −1.250; p = 0.000; and OR, −0.830, 95% CI, −1.194 to −0.465; p = 0.000, respectively). A lower incidence of sepsis was found in patients treated with G-CSF (RR, 0.367; 95% CI, 0.158 to 0.854; p = 0.020). G-CSF therapy significantly increased survival rate in LF patients (RR, 2.25; 95% CI, 1.517 to 3.338; p = 0.000).Conclusions: The results of this meta-analysis indicate that G-CSF treatment in patients with LF significantly improved liver function, reduced the incidence of sepsis, and prolonged short-term survival.

show abstract

Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease

Colli

Fraquelli

Prati

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Mechanism and Efficacy of Mobilization of Granulocyte Colony-Stimulating Factor in the Treatment of Chronic Hepatic Failure

Cited by 5 publications

References 0 publications

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

Expression Profiles of Circulating Cytokines, Chemokines, and Immune Cells in Patients With Hepatitis B Virus Infection

Effects of Granulocyte Colony-Stimulating Factor on Patients with Liver Failure: a Meta-Analysis

Granulocyte colony-stimulating factor with or without stem or progenitor cell or growth factors infusion for people with compensated or decompensated advanced chronic liver disease

Contact Info

Product

Resources

About